View Mobile Friendly Conference List »

Setting new standards in information exchange for the pharmaceutical and biotech industry


Top 10 Medical Research Issues and Trends to Watch in 2016

  • January 11, 2016

  • MargaretAndreson(1)

    Margaret Anderson at the R&D Leadership Summit 2015

    Conference Forum speaker and Executive Director of FasterCures, Margaret Anderson released FasterCure’s recommendations on the Top 10 Medical Research Issues and Trends to Watch in 2016.

    Patient engagement is listed as the number one priority on their top 10 list. They talk about the importance of patient input on R&D and how patient involvement needs to become a discipline that is scalable and actionable.

    The 3rd Annual Patients as Partners program hosted by The Conference Forum plans on showcasing how the discussion around patient involvement/engagement can be turned into action by providing tangible strategies. Additionally, the program addresses many of the issues and trends that FasterCures identifies in their survey including value frameworks, drug pricing, FDA perspectives, amongst many others. Margaret Anderson will be moderating a panel at the event on the topic of value, coverage and reimbursement.


    AAEAAQAAAAAAAATXAAAAJDA3OWE0MmU4LWExZjEtNGEyMS04ZGMzLTU5ZmNkYWFlNzZjMQAdvances in scientific discovery are converging with unparalleled policy and regulatory action for medical research. At FasterCures, we have surveyed the landscape and interviewed subject matter experts to come up with our recommendations of the top 10 issues to keep an eye on in 2016:



    1. Patient engagement: Put a ring on it (with apologies to Beyoncé)
    Patient engagement was the “hot date” of 2015, and it’s about time, right? Now, 2016 must be about turning it into a lasting commitment before the passion fades. Anecdotal evidence is building about the positive impact of patient input on R&D efficiency and effectiveness, but this needs to become a discipline that is scalable and actionable. Methods for collecting and applying patient perspective data must be created and consensus built around them. Skills and capacities need to be built in organizations, from industry to patient groups to regulators and, yes, even payers. Concerns about conflict-of-interest must be addressed. The U.S. Food and Drug Administration (FDA) is leading the way by offering guidance on incorporating patient preferences into clinical trial designs and using those data to inform approval decisions; its new Patient Engagement Advisory Committee will convene in 2016.

    Read the full article here:

    For more information about the 3rd Annual Patients as Partners conference visit:

    *Patients as Partners is a accredited event.